N/A N=25 Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
Melanoma · Advanced Melanoma
Primary: Number of Genes Predictive of Response at Baseline — 52 genes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=140 Prostate Cancer - Patient Empowerment Program
Prostate Cancer
Primary: Proportion of Participants With Clinically Significant Psychological Distress (Kessler Psychological Distress Scale-10 ≥20) — 9; 14; 57; 48 Participants — p=0.031
N/A N=64 Diabetes Data-Assisted Remission Trial (DDART)
Type 2 Diabetes · Obesity
Primary: Change in Body Weight — -10.73; -6.15; -9.09 kg
Phase 1 N=16 Subcutaneous Abatacept in Renal Transplant Recipients
Kidney Transplant Recipient
Primary: Number of Participants Who Are Compliant With Self-administration — 8; 5; 1 Participants
Phase 2 N=150 Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma · Metastatic Pancreatic Cancer
Primary: Regimen Limiting Toxicity — 0; 0; 0 Participants
Phase 3 N=564 Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
Functional Dyspepsia
Primary: Change in the Overall Severity of Functional Dyspepsia Between Baseline and Week 8, as Measured by the LDQ Severity Score — -9.54; -9.17 units on a scale
Phase 3 N=959 A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Primary: Hemagglutination Inhibition (HI) Antibody Titers Against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza Vaccine Strains 29 Days After the Administration of High-Dose…
N/A N=38 Sun Protection and Tanning Awareness in Rural Schools
Melanoma · Adolescents
Primary: Sun Protection Index Scores - Weekday — .179 score on a scale
N/A N=28 Impact of 2 Resuscitation Sequences on Management of Simulated Pediatric Cardiac Arrest
Cardiopulmonary Arrest · Pediatric ALL · Resuscitation
Primary: Median Alveolar Ventilation — 276; 370 ml
N/A N=20 Immunological Response After Shrimp Oral Immunotherapy Treatment
Allergy to Shrimp · Immunotherapy
Primary: Change in Eliciting Dose of Shrimp During Oral Food Challenge — 3233; 25 mg
N/A N=422 Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication
End-stage Renal Disease · Chronic Kidney Diseases
Primary: Living Donor Inquiry — 16.0; 18.6 Percentage of participants — p=0.507
Early Phase 1 N=125 mHealth to Help Pregnant and Postpartum Women in Recovery for Opioid Use Disorder
Opioid Use Disorders
Primary: Cravings — 11.90; 8.94; 11.10; 8.21 score on a scale (total score, 0 to 30) — p=0.12
N/A N=116 JETi Lower Extremity Venous Thrombosis
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
Phase 2 N=43 Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
Dementia With Lewy Bodies
Primary: Safety and Tolerability: Occurrence of Adverse Events (AEs) — 2; 2; 74; 37 events
Phase 1 N=13 Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW
HIV · Prophylaxis · Transgender
Primary: Change in Maximum Tenofovir Plasma (Cmax) Concentration — 286; 276; 274; 277 ng/mL